Phibro Animal Health Corporation - Asset Resilience Ratio
Phibro Animal Health Corporation (PAHC) has an Asset Resilience Ratio of 1.35% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Phibro Animal Health Corporation debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Phibro Animal Health Corporation's Asset Resilience Ratio has changed over time. See Phibro Animal Health Corporation net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Phibro Animal Health Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Phibro Animal Health Corporation stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $19.02 Million | 1.35% |
| Total Liquid Assets | $19.02 Million | 1.35% |
Asset Resilience Insights
- Limited Liquidity: Phibro Animal Health Corporation maintains only 1.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Phibro Animal Health Corporation Industry Peers by Asset Resilience Ratio
Compare Phibro Animal Health Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Phibro Animal Health Corporation (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Phibro Animal Health Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.66% | $9.00 Million | $1.36 Billion | -3.82pp |
| 2024-06-30 | 4.48% | $44.00 Million | $982.18 Million | +0.36pp |
| 2023-06-30 | 4.12% | $40.00 Million | $971.40 Million | +2.29pp |
| 2022-06-30 | 1.82% | $17.00 Million | $931.70 Million | -3.29pp |
| 2021-06-30 | 5.11% | $43.00 Million | $841.33 Million | -1.90pp |
| 2020-06-30 | 7.01% | $55.00 Million | $784.10 Million | +3.71pp |
| 2019-06-30 | 3.30% | $24.00 Million | $726.67 Million | -4.14pp |
| 2018-06-30 | 7.44% | $50.00 Million | $671.68 Million | +7.01pp |
| 2017-06-30 | 0.43% | $2.69 Million | $623.40 Million | -0.07pp |
| 2016-06-30 | 0.50% | $3.03 Million | $610.37 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $493.32 Million | -- |
| 2014-06-30 | 0.00% | $0.00 | $472.32 Million | -- |
About Phibro Animal Health Corporation
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including po… Read more